Federal Circuit holds Novo Nordisk patent invalid

21-06-2013

The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.


Novo Nordisk, Caraco, Federal Circuit

LSIPR